Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31616423 | 1.00 | CTNNB1 (0.50) | CTNNB1SLC6A4TDP1CYP1A2CYP2C19 | |
| SCHEMBL10729965 | 0.82 | CTNNB1 (0.54) | CTNNB1SLC6A4TDP1CYP1A2CYP2C19 | |
| SCHEMBL8329891 | 0.82 | MTNR1A (0.44) | CTNNB1SLC6A4TDP1CYP1A2CYP2C19 | |
| SCHEMBL18912285 | 0.81 | CYP1A2 (0.47) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL3681421 | 0.80 | CYP1A2 (0.52) | CTNNB1SLC6A4TDP1CYP1A2CYP2C19 | |
| SCHEMBL9518025 | 0.80 | SIGMAR1 (0.46) | SLC6A4TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL29190507 | 0.78 | CTNNB1 (0.50) | CTNNB1SLC6A4TDP1CYP1A2CYP2C19 | |
| SCHEMBL3003489 | 0.78 | SIGMAR1 (0.50) | CTNNB1SLC6A4TDP1CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL9734418 | 0.77 | SLC6A4 (0.47) | CTNNB1SLC6A4TDP1CYP1A2CYP2C19 | |
| SCHEMBL28072412 | 0.77 | SLC1A3 (0.48) | SLC6A4TDP1CYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109336887-B | Benzimidazole chiral heterocyclic compound and preparation method and application thereof | 中山大学 | 2021-12-17 | — | — | CN | claimed |
| US-12083140-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | FUTURE MEDICINE CO., LTD. (KR) | 2024-09-10 | — | — | US | disclosed |
| EP-3603647-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | FUTURE MEDICINE CO LTD (KR) | 2024-08-21 | — | — | EP | disclosed |
| CN-109336887-B | Benzimidazole chiral heterocyclic compound and preparation method and application thereof | 中山大学 | 2021-12-17 | — | — | CN | disclosed |
| US-20210386771-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | FUTURE MEDICINE CO., LTD. (KR) | 2021-12-16 | — | — | US | disclosed |
| US-11185556-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | FUTURE MEDICINE CO., LTD. (KR) | 2021-11-30 | — | — | US | disclosed |
| CN-113616659-A | Pharmaceutical composition containing adenosine derivative | 未来制药有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-109906083-B | Pharmaceutical composition containing adenosine derivative | 未来制药有限公司 | 2021-09-17 | — | — | CN | disclosed |
| EP-3603647-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | Future Medicine Co., Ltd. (KR) | 2020-02-05 | — | — | EP | disclosed |
| EP-2142549-B1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FM THERAPEUTICS CO LTD (KR) | 2013-07-10 | — | — | EP | disclosed |
| US-20100137577-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FUTURE MEDICINE CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
| EP-2142549-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FM Therapeutics Co., Ltd. (KR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008108508-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | FM THERAPEUTICS CO., LTD. (KR) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185556-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | ADORA1, ADORA2A, PDE3A | CTNNB1 1276/4885SLC6A4 879/4885TDP1 350/4885 |
| US-12083140-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | ADORA1, ADORA2A, ADORA3 | CTNNB1 1078/4885SLC6A4 889/4885TDP1 379/4885 |
| US-20210386771-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | ADORA1, ADORA2A, ADORA3 | CTNNB1 1078/4885SLC6A4 889/4885TDP1 379/4885 |
| US-20100137577-A1 | ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ADORA3, ADORA2A, ADORA1 | CTNNB1 2942/4885SLC6A4 2555/4885TDP1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.